Safe Pharmaceuticals

Safe Pharmaceuticals is a clinical-stage biopharmaceutical company specializing in the discovery and development of innovative small molecule therapies for metabolic and inflammatory diseases. The company's lead asset, SF-001, is a potent and selective agonist of the G protein-coupled receptor 120 (GPR120), also known as Free fatty acid receptor 4 (FFAR4), currently being evaluated in Phase 2 clinical trials for severe hypertriglyceridemia. Beyond lipid management, the company is advancing its pipeline to address non-alcoholic steatohepatitis (NASH) and other chronic metabolic disorders. With R&D operations in both Beijing and the United States, Safe Pharmaceuticals focuses on bridging global drug development expertise to address significant unmet medical needs in hepatology and cardiovascular health.